Navigation Links
Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Date:1/3/2012

AMSTERDAM, January 4, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its gene therapy program for the treatment of hemophilia B. Orphan designation in the U.S. could provide up to seven years market exclusivity on regulatory approval. Orphan designation for AMT's hemophilia program in the European Union was granted in November 2011.

AMT's hemophilia B program, which consists of an adeno-associated viral (AAV) vector containing the human factor IX gene, is being investigated in a Phase I/II study conducted by St. Jude's Children's Research Hospital (Memphis, USA) and University College London (UK). Promising data from an initial 6 patients, recently published in the New England Journal of Medicine (N Engl J Med 2011; 365:2357-2365), shows that gene therapy administration resulted in a reduced need for protein replacement treatment, the standard care for hemophilia patients.  AMT is preparing for additional clinical development work to establish safety, tolerability and proof-of-concept with a factor IX gene therapy produced using its proprietary AAV production system.

"U.S. orphan designation provides additional support for our hemophilia B gene therapy program and supplements the designation in the EU received in November," said Jörn Aldag, CEO of AMT. "The early clinical success seen with the program to date by our partners is very encouraging. We will build on this success in the coming months."  

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicl
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Calif. , Sept. 2, 2014  Xencor, ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today announced the appointment of ... development and the appointment of Lloyd Rowland ... general counsel. "Debra,s expertise in ...
(Date:9/2/2014)... Sept. 2, 2014  Spherix Incorporated (SPEX) -- an intellectual property ... intellectual property, today announced that the United States Patent ... Company in the month of August that are part ... The issued patents are: , ... August 19, 2014; and , U.S.RE45,095 issued August ...
(Date:9/1/2014)... The Collaborative R&D Terms and ... comprehensive understanding and unprecedented access to the collaborative ... worlds leading life science companies. , The report ... and why companies enter collaborative R&D deals. , ... deals terms provides critical insight into the negotiation ...
(Date:8/30/2014)... Dallas, TX (PRWEB) August 31, 2014 ... Industry is a professional and in-depth study on ... industry in Global and China. , The report ... definitions, applications and industry chain structure. Global market ... with a focus on history, developments, trends and ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3
... Kauten is taking direct aim at three unfavorable metrics, and ... , ,Kauten, CEO of QBI Life Sciences , recently ... Polymeric Micelles, a core product. The screening, which employed UGT1A1, ... is used to determine whether a drug will become active ...
... that is developing technologies for the $6 billion worldwide wound ... , ,The company, which was honored during an awards ceremony ... of 27 finalists that presented business plans to a panel ... which drew 200 entries, it will collect prizes of at ...
... Telecommunications, Inc. has introduced the Enhanced Mail Guardian, ... for organizational networks. , ,Enhanced Mail Guardian's features include ... be customized to handle encrypted e-mails that are specific ... sort e-mails and attachments based on key words like ...
Cached Biology Technology:QBI's PreserveX product passes initial test 2QBI's PreserveX product passes initial test 3MatriLab wins Governor's Business Plan Contest 2MatriLab wins Governor's Business Plan Contest 3MatriLab wins Governor's Business Plan Contest 4
(Date:9/1/2014)... and decisions of the Nomenclature Section of the XVIII ... July 2011. This meeting is held every six years ... the rules for naming algae, fungi and plants get ... naming the organisms they study. This is the primary ... for algae, fungi, and plants, which was published in ...
(Date:8/31/2014)... A fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria ... stomach cramps, has been developed by a team at ... the research team has demonstrated that it is possible ... which would lead to rapid diagnosis of the ... could be possible to identify different strains of the ...
(Date:8/31/2014)... of satellite data from the last 19 years reveals that ... the coast of Antarctica to rise by 2cm more than ... of Southampton detected the rapid rise in sea-level by studying ... million square kilometres. , The melting of the ... has contributed an excess of around 350 gigatonnes of freshwater ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2
... research shows an increased risk of ischemic stroke in postmenopausal ... found in baked goods, fried foods, and packaged products. Study ... journal published by Wiley-Blackwell on behalf of the American Neurological ... the stroke risk caused by a diet high in trans ...
... NY, February 29, 2012Although industrial parks are often ... which they reside, they can also consume environmental ... affect human health and quality of life. A ... ( http://www.liebertpub.com/ees ), a peer-reviewed journal from ...
... supercomputer has completed the first phase of an ... powerful scientific computing systems in the world. ... this month. The testing suite included leading scientific ... fusion, and combustion. Jaguar, manufactured by Cray ...
Cached Biology News:Postmenopausal women at greater risk of stroke from high trans fat intake 2Can industrial parks be more environmentally friendly? 2ORNL completes first phase of Titan supercomputer transition 2
... 1, active MW: 34.2kDa Formulation: 10mM ... Brij-35, 1mM dithiothreitiol with 50% glycerol ... to the Certificate of Analysis for ... salt precipitation followed by gel filtration ...
MitoScreen (JC-1) Kit , 100 tests Consult technical datasheet for details....
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Conjugate Quality Control Evaluation Specificity: Conjugate Quality Control Evaluation ...
Biology Products: